These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 34690116)

  • 21. Baseline results from the European non-interventional Antipsychotic Long acTing injection in schizOphrenia (ALTO) study.
    Llorca PM; Bobes J; Fleischhacker WW; Heres S; Moore N; Bent-Ennakhil N; Sapin C; Loze JY; Nylander AG; Patel MX
    Eur Psychiatry; 2018 Aug; 52():85-94. PubMed ID: 29734130
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Long acting injectable antipsychotics in the treatment of schizophrenia: a review of literature].
    Graffino M; Montemagni C; Mingrone C; Rocca P
    Riv Psichiatr; 2014; 49(3):115-23. PubMed ID: 25000887
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug Attitude, Insight, and Patient's Knowledge About Prescribed Antipsychotics in Schizophrenia: A Cross-Sectional Survey.
    Nagai N; Tani H; Yoshida K; Gerretsen P; Suzuki T; Ikai-Tani S; Mimura M; Uchida H
    Neuropsychiatr Dis Treat; 2020; 16():781-787. PubMed ID: 32256074
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of paliperidone palmitate one-month formulation on relapse prevention in patients with schizophrenia: A post-hoc analysis of a one-year, open-label study stratified by medication adherence.
    Si T; Li N; Lu H; Cai S; Zhuo J; Correll CU; Zhang L; Feng Y
    J Psychopharmacol; 2018 Jun; 32(6):691-701. PubMed ID: 29764266
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current and emerging long-acting antipsychotics for the treatment of schizophrenia.
    de Filippis R; De Fazio P; Gaetano R; Steardo L; Cedro C; Bruno A; Zoccali RA; Muscatello MRA
    Expert Opin Drug Saf; 2021 Jul; 20(7):771-790. PubMed ID: 33775184
    [No Abstract]   [Full Text] [Related]  

  • 26. "Impact of drug-reimbursement policies on prescribing: A case-study of a newly marketed long-acting injectable antipsychotic among relapsed schizophrenia patients".
    Jackson JW; Fulchino L; Rogers J; Mogun H; Polinski J; Henderson DC; Schneeweiss S; Fischer MA
    Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):95-104. PubMed ID: 29168261
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk of discontinuation of antipsychotic long-acting injections vs. oral antipsychotics in real-life prescribing practice: a community-based study.
    Verdoux H; Pambrun E; Tournier M; Bezin J; Pariente A
    Acta Psychiatr Scand; 2017 May; 135(5):429-438. PubMed ID: 28332704
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Depot and oral antipsychotics: patient preferences and attitudes are not the same thing.
    Patel MX; De Zoysa N; Bernadt M; David A
    J Psychopharmacol; 2009 Sep; 23(7):789-96. PubMed ID: 18583438
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changes in attitude towards LAI antipsychotic maintenance treatment: A two-year follow-up study.
    Pietrini F; D'Anna G; Tatini L; Talamba GA; Andrisano C; Calderani E; Manetti M; Rossi Prodi P; Ricca V; Ballerini A
    Eur Psychiatry; 2018 Sep; 53():58-65. PubMed ID: 29957369
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Physician and patient benefit-risk preferences from two randomized long-acting injectable antipsychotic trials.
    Katz EG; Hauber B; Gopal S; Fairchild A; Pugh A; Weinstein RB; Levitan BS
    Patient Prefer Adherence; 2016; 10():2127-2139. PubMed ID: 27799749
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patients' Knowledge about Prescribed Antipsychotics and Medication Adherence in Schizophrenia: A Cross-Sectional Survey.
    Nagai N; Tani H; Suzuki T; Ikai S; Gerretsen P; Mimura M; Uchida H
    Pharmacopsychiatry; 2017 Nov; 50(6):264-269. PubMed ID: 28675911
    [No Abstract]   [Full Text] [Related]  

  • 32. Antipsychotic treatment of psychotic disorders in forensic psychiatry: Patients' perception of coercion and its predictors.
    Horvath J; Steinert T; Jaeger S
    Int J Law Psychiatry; 2018; 57():113-121. PubMed ID: 29548498
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concurrent Oral Antipsychotic Drug Use Among Schizophrenia Patients Initiated on Long-Acting Injectable Antipsychotics Post-Hospital Discharge.
    Doshi JA; Pettit AR; Stoddard JJ; Zummo J; Marcus SC
    J Clin Psychopharmacol; 2015 Aug; 35(4):442-6. PubMed ID: 26075492
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study.
    Nielsen J; Jensen SO; Friis RB; Valentin JB; Correll CU
    Schizophr Bull; 2015 May; 41(3):627-36. PubMed ID: 25180312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Impact of Antipsychotic Formulations on Time to Medication Discontinuation in Patients with Schizophrenia: A Dutch Registry-Based Retrospective Cohort Study.
    van der Lee APM; Önsesveren I; Wierdsma AI; van Westrhenen R; Beekman ATF; de Haan L; Mulder NCL
    CNS Drugs; 2021 Apr; 35(4):451-460. PubMed ID: 33837915
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of oral versus long-acting antipsychotics on social functioning: A psychiatrists' survey in India.
    Gundugurti PR; Nagpal R; Sheth A; Narang P; Gawande S; Singh V
    Asian J Psychiatr; 2017 Dec; 30():88-93. PubMed ID: 28843143
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recognition of patients who would benefit from LAI antipsychotic treatment: how to assess adherence.
    Correll CU
    J Clin Psychiatry; 2014 Nov; 75(11):e29. PubMed ID: 25470105
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-Acting Injectable Antipsychotic Medications: Why Aren't They Used as Often as Oral Formulations?
    Limandri BJ
    J Psychosoc Nurs Ment Health Serv; 2019 Mar; 57(3):7-10. PubMed ID: 30835795
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: Part I-patient perspectives.
    Iyer S; Banks N; Roy MA; Tibbo P; Williams R; Manchanda R; Chue P; Malla A
    Can J Psychiatry; 2013 May; 58(5 Suppl 1):14S-22S. PubMed ID: 23945063
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical evolution of patients treated with aripiprazole long-acting injectable: a preliminary, prospective, observational study.
    García Álvarez JC; González Sánchez L; García Resa E; Bonete Llácer JM; Román Rodríguez A; Pecino Esquerdo B; Pérez Martínez E
    Int J Psychiatry Clin Pract; 2020 Mar; 24(1):10-17. PubMed ID: 31933402
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.